Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


EUCODIS Bioscience launches beta-lactamase for antibiotics and diagnostics industries


Vienna, Europe, June 4, 2009 – EUCODIS Bioscience, a company developing enzymes for the chemical, the pharmaceutical, and other industries, announced today that it has successfully launched its first commercial enzyme, a beta-lactamase. The product is manufactured by EUCODIS Bioscience and can be supplied in a GMP-compliant formulation. The Company will market its beta-lactamase to antibiotics manufacturers to improve quality control, to the diagnostics industry, and to research organizations. The Company estimates that its beta-lactamase has a market potential of up to EUR 5 million.

“The launch of a beta-lactamase for the antibiotics industry and other uses opens a new phase in the development of our organization,” said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. “The EUCODIS Bioscience team has demonstrated its capacity to cover the whole value-chain of an integrated enzyme supplier, from enzyme development, to manufacturing, and to marketing. This success adds momentum to our efforts to bring to market further products that we are currently developing. We will continue to provide our development expertise and our technology to industrial partners that want to increase their research and development efficiency.”

About EUCODIS Bioscience


EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.

EUCODIS Bioscience’ products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.


For more information, please visit www.eucodisbioscience.com


Company contact EUCODIS Bioscience:

Rudy Pandjaitan, PhD
CEO EUCODIS Bioscience
Brunner Strasse 59
A-1230 Vienna
AUSTRIA
+ 43-1-86634 9241
office@eucodisbioscience.com


Media contact EUCODIS Bioscience:


Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
office@butschbacher.net


Publisher Contact Information:

EUCODIS Bioscience
+ 43-1-86634 9241
office@eucodisbioscience.com

Company profile of EUCODIS Bioscience
Past press releases of EUCODIS Bioscience.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.